Cepheid releases molecular test for the detection of carbapenemase producing Gram-negative bacteria -
Cepheid (NASDAQ: CPHD) today announced the release of Xpert ® Carba -R, a molecular test the demand for fast and accurate detection of Gram-negative bacteria producing carbapenemase, to be marketed as a product IVD according to the European Directive in vitro medical devices diagnosis. The test runs on Cepheid GeneXpert of ® system, molecular diagnostic platform leader in the world. Xpert carba-R detects and differentiates the genes encoding the most common carbapenemases -. Reports five gene families that comprise 68 individual resistance genes known, including KPC, NDM, VIM, OXA-48 and IMP-1
"Carbapenemase- producing organisms were named for their ability to fight antibiotic carbapenems. - the last line of defense in our medical toolbox, "said John Bishop, president of Cepheid and CEO" Xpert carba-R provides healthcare institutions a necessary tool for the rapid detection and precise patients colonized by these multiresistant organisms to help prevent generalized epidemics and identify best infection control channels. "
carbapenemase producers () resistant organisms, or CROs, include Enterobacteriaceae, a family bacteria that normally live in the digestive system, including organizations such as Klebsiella pneumoniae and Escherichia coli. They are part of the normal bacteria in the human gut. However, carbapenemase producers also Pseudomonas aeruginosa Acinetobacter baumannii , and a variety of other nosocomial pathogens which have become resistant to antibiotics called carbapenems. Carbapenems are often referred to as the antibiotic of last resort and are usually reserved for severe life-threatening infections caused by multidrug resistant organisms. All these organisms are able to host and distribute these carbapenem resistance genes.
The emergence and global spread of producer organizations carbapenemase is a big concern for health services around the world. These bacteria are often resistant to all beta-lactam antibiotics and often co-resistant to most other antibiotics, leaving very few treatment options.
"The detection of patients carriers of microorganisms carbapenemase producers, with a differentiation between the five major families of resistance genes, can have a significant control of the infection impact. With results in less one hour, we have the advantage of rapid implementation of epidemiological measures to control the spread of these organisms, "said Dr. Rafael Canton, professor of microbiology at the Hospital Universitario Ramón y Cajal, Madrid, Spain.
carbapenemases of global significance include Klebsiella pneumonia carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), Verona integron-encoded metallo-β-lactamase (VIM), imipenemase metallo-β-lactamase ( IMP) and oxacillinase-48 (OXA-48). In 2014, KPC is the most common carbapenemase the US while OXA-48 is becoming the most important in most European countries.
"Like our other GeneXpert cartridges Xpert CARBA -R can be performed on a STAT basis. - No waiting for the results in batches Rapid identification of patients colonized allows health facilities to begin the immediate implementation of measures against the infection to prevent the spread in highly susceptible populations, "said David Persing, MD, Ph.D., Cepheid Chief medical and technology." the active screening high-risk patients has the added benefit of allowing clinicians to optimize segregation decisions and avoid unnecessary impact isolates. "
Healthy people rarely get CRO infections, which are usually associated infections found in patients in hospitals, nursing homes and other health facilities. Patients who require devices such as ventilators, urinary catheters or intravenous catheters, and patient care taking long courses of certain antibiotics are most at risk for CRO infections.
Xpert carba-R begins shipping this month as -IVD CE Mark product. For more information on the Cepheid GeneXpert systems or a complete menu of Xpert tests CE-IVD, visit www.cepheidinternational.com.
EmoticonEmoticon